Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post-Commercialization Milestone Payments

Executive Summary

Sales-based milestones are growing in value and in the number of deals that employ them. Licensees like them because they essentially pay for themselves and offset higher royalty fees. For licensers, they boost the headline value of the deal.

Sales-based milestone payments are an increasingly popular means of remuneration in alliances. Licensees pay these flat fees when the licensed product attains a predetermined sales goal. Licensees aren't averse to paying them, as, indeed, they pay for themselves. The licensers' investors, meanwhile, have tangible numbers to associate with a product's commercial success, an already difficult task that's even trickier for early-stage products, as so little can be predicted about the competitive landscape they'll eventually be launched into.

In the table below, we've compiled a list of some of the largest sales-based milestones announced since 2000. Notably, some of the deals' potential sales milestones exceed the total pre-commercialization value. And while most of those listed are for near-term products, sales-based milestone commitments are made at least as frequently in early-stage deals—although those deals' announcements tend to roll up all the deal's possible milestone payments into one eye-popping figure that assumes the licensed product's approval and market success, which, of course, is assuming a lot.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel